JP2013512263A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512263A5
JP2013512263A5 JP2012541335A JP2012541335A JP2013512263A5 JP 2013512263 A5 JP2013512263 A5 JP 2013512263A5 JP 2012541335 A JP2012541335 A JP 2012541335A JP 2012541335 A JP2012541335 A JP 2012541335A JP 2013512263 A5 JP2013512263 A5 JP 2013512263A5
Authority
JP
Japan
Prior art keywords
mitotic checkpoint
schmidt
compounds
present
pharmacological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012541335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512263A (ja
JP5805652B2 (ja
Filing date
Publication date
Priority claimed from EP09075527A external-priority patent/EP2343294A1/en
Application filed filed Critical
Publication of JP2013512263A publication Critical patent/JP2013512263A/ja
Publication of JP2013512263A5 publication Critical patent/JP2013512263A5/ja
Application granted granted Critical
Publication of JP5805652B2 publication Critical patent/JP5805652B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012541335A 2009-11-30 2010-11-17 置換トリアゾロピリジン Expired - Fee Related JP5805652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075527.3 2009-11-30
EP09075527A EP2343294A1 (en) 2009-11-30 2009-11-30 Substituted triazolopyridines
PCT/EP2010/006993 WO2011063907A1 (en) 2009-11-30 2010-11-17 Substituted triazolopyridines

Publications (3)

Publication Number Publication Date
JP2013512263A JP2013512263A (ja) 2013-04-11
JP2013512263A5 true JP2013512263A5 (enExample) 2013-12-26
JP5805652B2 JP5805652B2 (ja) 2015-11-04

Family

ID=42026745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541335A Expired - Fee Related JP5805652B2 (ja) 2009-11-30 2010-11-17 置換トリアゾロピリジン

Country Status (7)

Country Link
US (1) US8551980B2 (enExample)
EP (2) EP2343294A1 (enExample)
JP (1) JP5805652B2 (enExample)
CN (1) CN102858768B (enExample)
CA (1) CA2781914A1 (enExample)
ES (1) ES2439776T3 (enExample)
WO (1) WO2011063907A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080232A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080228A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2831710A1 (en) 2011-03-31 2012-10-04 Bayer Intellectual Property Gmbh Substituted benzimidazoles as mps-1 kinase inhibitors
US20140255392A1 (en) 2011-04-06 2014-09-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN104603136B (zh) * 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类
CA2914745A1 (en) * 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
JP2016520665A (ja) 2013-06-11 2016-07-14 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
KR20240144991A (ko) * 2022-03-04 2024-10-04 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH0690447B2 (ja) 1986-09-12 1994-11-14 コニカ株式会社 ハロゲン化銀写真感光材料
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
WO2003000659A1 (en) 2001-06-26 2003-01-03 Nissan Chemical Industries, Ltd. Heterocycloiminophenyl compounds and fungicides and insecticides for agricultural and horticultural use
ES2456696T3 (es) 2002-09-11 2014-04-23 Genentech, Inc. Composiciones y métodos para el diagnóstico y el tratamiento de tumores
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
AU2004303876A1 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
ATE533497T1 (de) 2005-12-27 2011-12-15 Genentech Inc Verfahren zur verwendung von hedgehog-kinase- antagonisten zur behandlung von hedgehog- vermittelten krebs
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
EP2468887A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
EP2212326A1 (en) * 2007-08-23 2010-08-04 AstraZeneca AB 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
UA102828C2 (en) 2007-11-27 2013-08-27 Целльзом Лимитед Amino triazoles as p13k inhibitors
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
PL2379548T3 (pl) 2008-12-19 2016-08-31 Leo Pharma As Triazolopirydyny jako inhibitory fosfodiesterazy do leczenia chorób skórnych
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EP2396324A1 (en) * 2009-02-13 2011-12-21 Fovea Pharmaceuticals Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
JP6168773B2 (ja) 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
US8367830B2 (en) 2009-05-20 2013-02-05 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application

Similar Documents

Publication Publication Date Title
JP2013512268A5 (enExample)
JP2013503824A5 (enExample)
JP2013512264A5 (enExample)
KR102961371B1 (ko) Dna-의존적 단백질 키나제 억제제
CN101848895B (zh) 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
Jhaveri et al. HSP90 inhibitors for cancer therapy and overcoming drug resistance
DOP2019000022A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
EP3746436A1 (en) Fused ring compounds
TW202045181A (zh) 細胞週期蛋白依賴性激酶2生物標記物及其用途
EP4048270A1 (en) Pharmaceutical combination of prmt5 inhibitors
JP2015512943A5 (enExample)
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2016533366A5 (enExample)
JP2021502386A (ja) Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
KR20180130575A (ko) 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
JP2018510193A (ja) Ｌｓｄ１阻害剤としてのヘテロ環式化合物
JP2017511311A5 (enExample)
WO2014145214A2 (en) Inhibitors of prmt5 and methods of their use
JP2010501572A5 (enExample)
HRP20171534T4 (hr) Derivati fosfora kao inhibitori kinaza
AU2018212647A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2014532751A5 (enExample)
BR112014027337A2 (pt) composições orgânicas para tratar doenças relacionadas com kras
JP2014508752A5 (enExample)
PH12014501832A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme